Paper Details

  1. Home
  2. Paper Details

A pilot study to evaluate the safety and efficacy of the long-acting interleukin-1 inhibitor rilonacept (interleukin-1 Trap) in patients with familial cold autoinflammatory syndrome.

Author: BarhamBeverly, Goldbach-ManskyRaphaela, KastnerDaniel L, MellisScott J, PapadopoulosJoanne H, PhamTuyet-Hang, PlehnSara, PucinoFrank, ShroffSharukh D, SnyderChristopher, WeinsteinSteven P, WesleyRobert A, WilsonMildred

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, N.I.H., IntramuralFunding provided by the NIH for research projects within the NIH.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This pilot study investigated the safety and efficacy of rilonacept (IL-1 Trap) in patients with familial cold autoinflammatory syndrome (FCAS), a condition caused by excessive interleukin-1beta (IL-1beta) secretion. The study aimed to assess the safety and potential benefits of rilonacept, a long-acting IL-1 receptor fusion protein, in treating FCAS.
Paper Details　
Original Abstract of the Article :
Familial cold autoinflammatory syndrome (FCAS) is caused by mutations in the CIAS1 gene, leading to excessive secretion of interleukin-1beta (IL-1beta), which is associated with cold-induced fevers, joint pain, and systemic inflammation. This pilot study was conducted to assess the safety and effica...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://pubmed.ncbi.nlm.nih.gov/18668591

データ提供：米国国立医学図書館（NLM）

Rilonacept: A Novel Treatment for Familial Cold Autoinflammatory Syndrome

This pilot study investigates the safety and efficacy of rilonacept (IL-1 Trap), a novel treatment for familial cold autoinflammatory syndrome (FCAS). FCAS is a rare genetic disorder characterized by episodes of fever, joint pain, and inflammation triggered by cold exposure. The study found that rilonacept was well-tolerated and showed promising results in reducing FCAS symptoms.

Rilonacept: A Potential Breakthrough for Familial Cold Autoinflammatory Syndrome

The research suggests that rilonacept is a promising treatment option for FCAS, offering potential relief from the debilitating symptoms of this rare genetic disorder. Its effectiveness in reducing inflammation and its favorable safety profile make it a valuable tool for managing FCAS.

Understanding Familial Cold Autoinflammatory Syndrome

Familial cold autoinflammatory syndrome (FCAS) is a rare genetic disorder that affects the immune system. It is characterized by episodes of fever, joint pain, and inflammation, often triggered by cold exposure. Rilonacept is a medication that specifically targets the inflammatory pathway involved in FCAS.

Dr.Camel's Conclusion

This pilot study provides a glimmer of hope for individuals suffering from familial cold autoinflammatory syndrome. Rilonacept offers a potential treatment option that could significantly improve the quality of life for those affected by this rare disorder.
Date :
  1. Date Completed 2008-09-18
  2. Date Revised 2022-03-09
Further Info :

Pubmed ID

18668591

DOI: Digital Object Identifier

NIHMS149037

Related Literature

Article Analysis
・Effects of rilonacept injection
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.